Chemotherapy and anti-epileptic drug interactions

Handbook of Brain Tumor Chemotherapy

Volumn , Issue , 2006, Pages 44-57

  Fink, Karen L ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053087724     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088410-0/50041-X     Document Type: Chapter

References (117)

1. Cohen N., Strauss G., Lew R., Silver D., Recht L. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988, 6:1621-1624.
2. Forsyth P.A., Weaver S., Fulton D., et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003, 30:106-112.
3. Liigant A., Haldre S., Oun A., et al. Seizure disorders in patients with brain tumors. Eur Neurol 2001, 45:46-51.
4. Maytal J., Grossman R., Yusuf F.H., et al. Prognosis and treatment of seizures in children with acute lymphoblastic leukemia. Epilepsia 1995, 36:831-838.
5. Pace A., Bove L., Innocenti P., et al. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998, 17:479-484.
6. Im S.H., Chung C.K., Cho B.K., et al. Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery. J Neurooncol 2002, 59:173-181.
7. Razack N., Baumgartner J., Bruner J. Pediatric oligodendrogliomas. Pediatr Neurosurg 1998, 28:121-131.
8. Moots P.L., Maciunas R.J., Eisert D.R., Parker R.A., Laporte K., Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995, 52:717-727.
9. Hirsch J.F., Sainte Rose C., Pierre-Kahn A., Pfister A., Hoppe-Hirsch E. Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J Neurosurg 1989, 70:568-575.
10. Oberndorfer S., Schmal T., Lahrmann H., Urbanits S., Lindner K., Grisold W. The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna. Wien Klin Wochenschr 2002, 114:911-919.
11. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22(14):2865-2872.
12. van den Bent M.J. The role of chemotherapy in brain metastases. Eur J Cancer 2003, 39:2114-2120.
13. Hauser W.A., Annegers J.F., Kurland L.T. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993, 34:453-454.
14. Chandramouli J. Newer anticonvulsant drugs in neuropathic pain and bipolar disorder. J Pain Palliat Care Pharmacother 2002, 16:19-37.
15. Levendoglu F., Ogun C.O., Ozerbil O., Ogun T.C., Ugurlu H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 2004, 29:743-747.
16. McCleane G. Pharmacological management of neuropathic pain. CNS Drugs 2003, 17:1031-1043.
17. Silberstein S.D., Neto W., Schmitt J., Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004, 61:490-495.
18. Freitag F.G., Collins S.D., Carlson H.A., et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002, 58:1652-1659.
19. Sabatowski R., Galvez R., Cherry D.A., et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004, 109:26-35.
20. Modi S., Pereira J., Mackey J.R. The cancer patient with chronic pain due to herpes zoster. Curr Rev Pain 2000, 4:429-436.
21. Hardoy M.C., Hardoy M.J., Carta M.G., Cabras P.L. Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients. J Affect Disord 1999, 54:315-317.
22. Pedley T.A., Guilleminault C. Episodic nocturnal wanderings responsive to anticonvulsant drug therapy. Ann Neurol 1977, 2:30-35.
23. Shimoda M., Nakayasu H., Nakashima K., Shimomura T., Takahashi K. Effective anticonvulsant therapy in a patient with limb shaking: a case report. Psychiatry Clin Neurosci 1995, 49:71-72.
24. Goldsmith D.R., WagstaffA.J., Ibbotson T., Perry C.M. Lamotrigine: A review of its use in bipolar disorder. Drugs. 2003, 63:2029.
25. Kim E. The use of newer anticonvulsants in neuropsychiatric disorders. Curr Psychiatry Rep 2002, 4:331-337.
26. DelBello M.P., Kowatch R.A., Warner J., et al. Adjunctive topiramate treatment for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 2002, 12:323-330.
27. Patsalos P.N., Froscher W., Pisani F., van Rijn C.M The importance of drug interactions in epilepsy therapy. Epilepsia 2002, 43:365-385.
28. Gronemeyer H., Gustafsson J.A., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004, 3:950-964.
29. Johnson D.R., Klaassen C.D. Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. Toxicol Sci 2002, 67:182-189.
30. Swales K., Negishi M. CAR, driving into the future. Mol Endocrinol 2004, 18:1589-1598.
31. Goodwin B., Moore J.T. CAR: detailing new models. Trends Pharmacol Sci 2004, 25:437-441.
32. Sueyoshi T., Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 2001, 41:123-143.
33. Huang W., Zhang J., Chua S.S., et al. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). PNAS 2003, 100:4156-4161.
34. Saini S.P., Sonoda J., Xu L., et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol 2004, 65:292-300.
35. de Wildt S.N., Kearns G.L., Leeder J.S., van den Anker J.N. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999, 36:439-452.
36. Toffoli G., Cecchin E., Corona G., Boiocchi M. Pharmacogenetics of irinotecan. Curr Med Chem Anti-Canc Agents 2003, 3:225-237.
37. Vecht C.J., Wagner G.L., Wilms E.B. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003, 2:404-409.
38. Kivisto K.T., Kroemer H.K., Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995, 40:523-530.
39. Nallani S.C., Glauser T.A., Hariparsad N., et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 2003, 44:1521-1528.
40. Ueda A., Hamadeh H.K., Webb H.K., et al. Diverse roles of the nuclear orphan receptor car in regulating hepatic genes in response to phenobarbital. Mol Pharmacol 2002, 61:1-6.
41. Harris J., Rahman A., Kim B., Guengerich F., Collins J. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994, 54:4026-4035.
42. Rahman A., Korzekwa K., Grogan J., Gonzalez F., Harris J. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994, 54:5543-5546.
43. Desai P.B., Duan J.Z., Zhu Y.W., Kouzi S. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 1998, 23:417-424.
44. Vecht C.J., Wagner G.L., Wilms E.B. Treating seizures in patients with brain tumors: Drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 2003, 30:49-52.
45. Wagner G.L., Wilms E.B., Vecht Ch J. Levetiracetam: an anti-epileptic drug with interesting pharmacokinetic properties. Ned Tijdschr Geneeskd 2002, 146:1218-1221.
46. Bourg V., Lebrun C., Chichmanian R.M., Thomas P., Frenay M. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001, 12:217-219.
47. Baker A.F., Dorr R.T. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001, 27:221-233.
48. Chang S., Kuhn J., Rizzo J., et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1998, 16:2188-2194.
49. Chang S.M., Kuhn J.G., Robins H.I., et al. A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer 2001, 91:417-422.
50. Grossman S.A., Hochberg F., Fisher J., et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol 1998, 42:118-126.
51. Prados M.D., Yung W.K., Jaeckle K.A., et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncol 2004, 6:44-54.
52. Cloughesy T.F., Filka E., Kuhn J., et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003, 97:2381-2386.
53. Gilbert M., Supko J., Grossman S., Mikkelsen T., Priet R., Carson K. Dose requirements, pharmacology and activity of CPT-11 in patients with recurrent high-grade glioma. A NABTT CNC Consortium trial. Proc Am Soc Clin Oncol 2000, 19:A622.
54. Gilbert M.R., Supko J.G., Batchelor T., et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003, 9:2940-2949.
55. Kuhn J.G. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Huntington) 2002, 16:33-40.
56. Prados M., Chang S., Burton E., et al. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc Am Soc Clin Oncol 2003, 22:99.
57. Prados M.D., Yung W.A., Wen P.Y., et al. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. J Clin Oncol 2004, 22:108.
58. Lieberman F.S., Cloughesy T., Malkin M., et al. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. Proc Am Soc Clin Oncol 2003, 22:103.
59. Lieberman F.S., Cloughesy T.F., Fine H.A., et al. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. J Clin Oncol 2004, 22:109.
60. Yung A., Vredenburgh J., Cloughesy T., et al. Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial. J Clin Oncol 2004, 22:120.
61. Chakravarti A., Seiferheld W., Robins H.I., et al. An update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib+radiation for newly-diagnosed glioblastoma (GBM) patients. J Clin Oncol 2004, 22:124.
62. Schroder H., Ostergaard J.R. Interference of high-dose methotrexate in the metabolism of valproate?. Pediatr Hematol Oncol 1994, 11:445-449.
63. Schering-Plough Temozolomide [package insert] 2004, Schering-Plough, Philadelphia.
64. Chalk J., Ridgeway K., Brophy T., Yelland J., Eadie M. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 1984, 47:1087-1090.
65. Gambertoglio J.G., Holford N.H., Kapusnik J.E., et al. Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. Kidney Int 1984, 25:119-123.
66. Brooks S.M., Werk E.E., Ackerman S.J., Sullivan I., Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 1972, 286:1125-1128.
67. Liddle C., Goodwin B.J., George J., Tapner M., Farrell G.C. Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab 1998, 83:2411-2416.
68. Pascussi J.M., Gerbal-Chaloin S., Fabre J.M., Maurel P., Vilarem M.J. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 2000, 58:1441-1450.
69. Grossman S.A., Sheidler V.R., Gilbert M.R. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 1989, 87:505-510.
70. Neef C., de Voogd-van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 1988, 43:372-375.
71. Gilbar P., Brodribb T. Phenytoin and fluorouracil interaction. Ann Pharmacother 2001, 35:1367-1370.
72. Rich J.N., Reardon D.A., Peery T., et al. Phase II Trial of Gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22:133-142.
73. Raizer J.J., Abrey L.E., Wen P., et al. A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. J Clin Oncol 2004, 22:107.
74. Relling M.V., Pui C.H., Sandlund J.T., et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000, 356:285-290.
75. Acharya S., Bussel J.B. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000, 22:62-65.
76. Chambers H.G., Weinstein C.H., Mubarak S.J., Wenger D.R., Silva P.D. The effect of valproic acid on blood loss in patients with cerebral palsy. J Pediatr Orthop 1999, 19:792-795.
77. Serdaroglu G., Tutuncuoglu S., Kavakli K., Tekgul H. Coagulation abnormalities and acquired von Willebrand's disease type 1 in children receiving valproic acid. J Child Neurol 2002, 17:41-43.
78. Zeller J.A., Schlesinger S., Runge U., Kessler C. Influence of valproate monotherapy on platelet activation and hematologic values. Epilepsia 1999, 40:186-189.
79. Ward M.M., Barbaro N.M., Laxer K.D., Rampil I.J. Preoperative valproate administration does not increase blood loss during temporal lobectomy. Epilepsia 1996, 37:98-101.
80. Winter S.L., Kirel R.L., Novacheck T.F., Luxenberg M.G., Leutgeb V.J., Erickson P.A. Perioperative blood loss: the effect of valproate. Pediatr Neurol 1996, 15:19-22.
81. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004, 62:1252-1260.
82. GlaxoSmithKline Lamictal [package insert] 2004, GlaxoSmithKline, Kenilworth, NJ.
83. FDA. Trileptal [FDA-approved package insert]. FDA, Washington, DC.
84. Novartis Tegretol [package insert] 2003, Novartis, Research Triangle Park, NC.
85. Delattre J.Y., Safai B., Posner J.B. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 1988, 38:194-198.
86. Mamon H.J., Wen P.Y., Burns A.C., Loeffler J.S. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 1999, 40:341-344.
87. Micali G., Linthicum K., Han N., West D.P. Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Pharmacotherapy 1999, 19:223-227.
88. Aguiar D., Pazo R., Duran I., et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 2004, 66:345-350.
89. Delattre J., Safai B., Posner J. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 1988, 38:194-198.
90. Lehmann D.F., Hurteau T.E., Newman N., Coyle T.E. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther 1997, 62:225-229.
91. Khan R.B., Hunt D.L., Thompson S.J. Gabapentin to control seizures in children undergoing cancer treatment. J Child Neurol 2004, 19:97-101.
92. Wagner G.L., Wilms E.B., Van Donselaar C.A., Vecht Ch J. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 2003, 12:585-586.
93. Stevens G.H.J, Vogelbaum M.A., Suh J.A., Peereboom D.M., Barnett G.H. Levetiracetam use in brain tumor patients. Neurology 2005, 64:A48. P01.066.
94. Burstein A.H., Fisher K.M., McPherson M.L., Roby C.A. Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base. Pharmacotherapy 2000, 20:562-567.
95. Chang S.W., da Silva J.H., Kuhl D.R. Absorption of rectally administered phenytoin: a pilot study. Ann Pharmacother 1999, 33:781-786.
96. Kanner A.M., Bourgeois B.F., Hasegawa H., Hutson P. Rapid switchover to carbamazepine using pharmacokinetic parameters. Epilepsia 1998, 39:194-200.
97. Schaffler L., Bourgeois B.F., Luders H.O. Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. Epilepsia 1994, 35:195-198.
98. Hassan M., Oberg G., Bjorkholm M., Wallin I., Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993, 33:181-186.
99. Minami H., Lad T.E., Nicholas M.K., Vokes E.E., Ratain M.J. Pharmacokinetics and Pharmacodynamics of 9-Aminocamptothecin Infused Over 72 Hours in Phase II Studies. Clin Cancer Res 1999, 5:1325-1330.
100. Murry D.J., Cherrick I., Salama V., et al. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol 2002, 24:130-133.
101. Rabinowicz A.L., Hinton D.R., Dyck P., Couldwell W.T. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 1995, 36:513-515.
102. Villikka K., Kivisto K.T., Maenpaa H., Joensuu H., Neuvonen P.J. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999, 66:589-593.
103. Herendeen J.M., Smith D.A., Stead A., Bowen C., Koch K.M., Beelen A.P. An open-label, fixed sequence, two period study to evaluate the potential induction of GW572016 metabolism by carbamazepine. J Clin Oncol 2004, 22:215.
104. Zamboni W., Gajjar A., Heideman R., et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998, 4:783-789.
105. Bill P.A., Vigonius U., Pohlmann H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997, 27:195-204.
106. Dam M., Ekberg R., Loyning Y., Waltimo O., Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989, 3:70-76.
107. Chadwick D., Anhut H., Greiner M., et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998, 51:1282-1288.
108. Brodie M.J., Overstall P.W., Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999, 37:81-87.
109. Brodie M.J., Richens A., Yuen A.W. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995, 345:476-479.
110. Steiner T.J., Dellaportas C.I., Findley L.J., et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999, 40:601-607.
111. Gilliam F.G., Veloso F., Bomhof M.A.M., et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003, 60:196-202.
112. Privitera M.D., Brodie M.J., Mattson R.H., Chadwick D.W., Neto W., Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003, 107:165-175.
113. Guerreiro M.M., Vigonius U., Pohlmann H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997, 27:205-213.
114. Frank L.M., Enlow T., Holmes G.L., et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999, 40:973-979.
115. Gilliam F.G., Veloso F., Bomhof M.A., et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003, 60:196-202.
116. Handschin C., Meyer U.A. Induction of Drug Metabolism: The Role of Nuclear Receptors. Pharmacol Rev 2003, 55:649-673.
117. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 1998, 23:403-416.